Background: Correct pre-therapeutic staging of the first primary carcinoma (FPC) and detection of simultaneous second primary carcinomas (SSPCs) decisively influence therapy and prognosis of head and neck squamous cell carcinomas (HNSCC). The aim of this study was to determine the benefit of pre-therapeutic triple endoscopy for detection of SSPC and pre-therapeutic T category. Methods: A cohort of 234 HNSCC patients with completed triple endoscopy was reviewed, focusing on pre-therapeutic T category and SSPC. Risk stratification for different subsites was evaluated. Results: The risk for SSPC was 5.56%. FPC of the oral cavity and oropharynx had the highest prevalence of SSPC (46.15%, 38.46%); most SSPCs were found in the hypopharynx. No SSPCs were found in the oral cavity, nasopharynx and oesophagus. Significant results in correct pre-therapeutic T staging have been achieved for the larynx (p = 0.021) and the oropharynx (p = 0.001). Conclusions: Triple endoscopies seem to be inadequate for SSPC detection in HNSCC patients. Endoscopies of the trachea and oesophagus should be reconsidered. Alternatively, risk-directed endoscopies of the hypopharynx might be performed in patients with oral cancer. For evaluation of resectability, conducting triple endoscopy could be reduced to a single endoscopy because the complication rate is low and pre-therapeutic T staging can be improved.

Journal Section:
Research Article
Keywords:
Head and neck cancer, Triple endoscopy, Panendoscopy, Simultaneous second primarycarcinoma, Staging
1.
Rennemo E, Zätterström U, Boysen M: Synchronous second primary tumors in 2,016 head and neck cancer patients: Role of symptom-directed panendoscopy. Laryngoscope 2011;121:304-309.
2.
Sharma SJ, Linke JJ, Kroll T, et al., Praxis der Tumorendoskopie an deutschen HNO-Kliniken. Laryngorhinootologie 2013;92:166-169.
3.
McGuirt WF, Matthews B, Koufman JA: Multiple simultaneous tumors in patients with head and neck cancer. A prospective, sequential panendoscopic study. Cancer 1982;50:1195-1199.
4.
Guardiola E, Chaigneau L, Villanueva C, Pivot X: Is there still a role for triple endoscopy as part of staging for head and neck cancer? Curr Opin Otolaryngol Head Neck Surg 2006;14:85-88.
5.
Klussmann JP, Knoedgen R, Wittekindt C, et al.: Complications of suspension laryngoscopy. Ann Otol Rhinol Laryngol 2002;111:972-976.
6.
Haughey BH, Gates GA, Arfken CL, Harvey J: Meta-analysis of second malignant tumors in head and neck cancer: The case for an endoscopic screening protocol. Ann Otol Rhinol Laryngol 1992;101:105-112.
7.
Boute P, Page C, Biet A, et al.: Epidemiology, prognosis and treatment of simultaneous squamous cell carcinomas of the oral cavity and hypopharynx. Eur Ann Otorhinolaryngol Head Neck Dis 2014;131:283-287.
8.
Baumann I, Plinkert PK: Die Panendoskopie Sinnvolle Routinemethode beim Staging der Plattenepithelkarzinome des oberen Aerodigestivtrakts? HNO 1996;44:489-491.
9.
Shaha A, Hoover E, Marti J, Krespi Y: Is routine triple endoscopy cost-effective in head and neck cancer? Am J Surg 1988;155:750-753.
10.
Rennemo E, Zätterström U, Boysen M: Impact of second primary tumors on survival in head and neck cancer: An analysis of 2,063 cases. Laryngoscope 2008;118:1350-1356.
11.
McGarry GW, Mackenzie K, Periasamy P, et al.: Multiple primary malignant tumours in patients with head and neck cancer: the implications for follow-up. Clin Otolaryngol Allied Sci 1992;17:558-562.
12.
Atkins JP Jr, Keane WM, Young KA, Rowe LD: Value of panendoscopy in determination of second primary cancer. A study of 451 cases of head and neck cancer. Arch Otolaryngol 1984;110:533-534.
13.
Dammer R, Bonkowski V, Kutz R, et al.: [Early detection of multiple tumors in primary diagnosis of oral carcinomas using panendoscopy]. Mund Kiefer Gesichtschir 1999;3:61-66.
14.
Skinner LJ, Timon CI: Panendoscopy and bronchial washings: Role and efficacy in detection of simultaneous primary head and neck cancers. J Laryngol Otol 2000;114:690-693.
15.
Morita FH, Bernardo WM, Ide E, et al.: Narrow band imaging versus lugol chromoendoscopy to diagnose squamous cell carcinoma of the esophagus: A systematic review and meta-analysis. BMC Cancer 2017;17:54.
16.
Gan SJ, Dahlstrom KR, Peck BW, et al.: Incidence and pattern of second primary malignancies in patients with index oropharyngeal cancers versus index nonoropharyngeal head and neck cancers. Cancer 2013;119:2593-2601.
17.
Milano MT, Peterson CR 3rd, Zhang H, et al.: Second primary lung cancer after head and neck squamous cell cancer: Population-based study of risk factors. Head Neck 2012;34:1782-1788.
18.
Fakhry N, Barberet M, Lussato D, et al.: [Role of []18]-FDG PET/CT in the initial staging of head and neck cancers]. Rev Laryngol Otol Rhinol (Bord) 2007;128:3-9.
19.
Fakhry N, Lussato D, Jacob T, et al.: Comparison between PET and PET/CT in recurrent head and neck cancer and clinical implications. Eur Arch Otorhinolaryngol 2007;264:531-538.
20.
Højgaard L, Specht L: PET/CT in head and neck cancer. Eur J Nucl Med Mol Imaging 2007;34:1329-1333.
21.
Rodriguez-Bruno K, Ali MJ, Wang SJ: Role of panendoscopy to identify synchronous second primary malignancies in patients with oral cavity and oropharyngeal squamous cell carcinoma. Head Neck 2011;33:949-953.
22.
Kerawala CJ, Bisase B, Lee J: The use of examination under anaesthesia and panendoscopy in patients presenting with oral cavity and oropharyngeal squamous cell carcinoma. Ann R Coll Surg Engl 2009;91:609-612.
© 2018 S. Karger GmbH, Freiburg
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2018
You do not currently have access to this content.